SCHEMBL1758084

SCHEMBL1758084

O=COc1cccc2c1ccc1ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 4/20 0.52
ALDH1A1 P00352 5/20 0.44
TDP1 Q9NUW8 4/20 0.44
HSD17B10 Q99714 3/20 0.44
CYP2A6 P11509 1/20 0.44
TSHR P16473 1/20 0.44
PAX8 Q06710 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.40
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
HPGD P15428 3/20 0.39
HIF1A Q16665 2/20 0.39
CYP1B1 Q16678 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946 0.88 ALDH1A1 (0.47) ALDH1A1TDP1HSD17B10L3MBTL1MAPT
SCHEMBL28814017 0.86 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10L3MBTL1MAPT
SCHEMBL27808337 0.86 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10L3MBTL1MAPT
SCHEMBL27786465 0.86 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10L3MBTL1MAPT
Methylamine SCHEMBL27386148 0.83 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10TSHRL3MBTL1
SCHEMBL28250584 0.81 ALDH1A1 (0.43) HPRT1ALDH1A1TDP1HSD17B10CYP2A6
SCHEMBL13899918 0.81 HPRT1 (0.52) HPRT1ALDH1A1TDP1HSD17B10CYP2A6
SCHEMBL28232293 0.80 ALDH1A1 (0.42) HPRT1ALDH1A1TDP1HSD17B10CYP2A6
SCHEMBL17291109 0.80 MAPT (0.38) ALDH1A1TDP1CYP2A6TSHRL3MBTL1
SCHEMBL27563208 0.79 GPR84 (0.50) HPRT1ALDH1A1TDP1HSD17B10CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116135782-B Preparation method of weak graphene oxide, weak graphene oxide and preparation method of graphene 江苏天奈科技股份有限公司 2025-02-14 CN claimed
CN-116135782-A Preparation method of weak graphene oxide, weak graphene oxide and preparation method of graphene 江苏天奈科技股份有限公司 2023-05-19 CN claimed
CN-115612483-A Regulation and control CsPbBr 3 Method for quantum dot excited state lifetime 中国科学院大连化学物理研究所 2023-01-17 CN claimed
CN-108269695-B A kind of supercapacitor graphene/carbon nano-tube electrode material and preparation method thereof 青岛科技大学 2019-10-08 CN claimed
CN-109836326-A A kind of metal-organic framework materials and preparation method and applications of the Cu based on benzophenanthrene Carboxylic acid ligand 北京工业大学 2019-06-04 CN claimed
CN-108269695-A A kind of ultracapacitor graphene/carbon nano-tube electrode material and preparation method thereof 青岛科技大学 2018-07-10 CN claimed
CN-104730031-A Method for determining chemical components of rosin by using near infrared spectrum technology RES INST SUBTROPICAL FORESTRY CAF 2015-06-24 CN claimed
US-20250064833-A1 COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS SAGE THERAPEUTICS, INC. 2025-02-27 US disclosed
CN-116135782-B Preparation method of weak graphene oxide, weak graphene oxide and preparation method of graphene 江苏天奈科技股份有限公司 2025-02-14 CN disclosed
CN-115612483-B Regulation and control CsPbBr3Method for prolonging service life of quantum dot excited state 中国科学院大连化学物理研究所 2024-11-15 CN disclosed
EP-4447953-A1 COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS Sage Therapeutics, Inc. (US) 2024-10-23 EP disclosed
WO-2024128000-A1 ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE 東京応化工業株式会社 2024-06-20 WO disclosed
WO-2024075474-A1 PARTICULATE COMPOSITION, COATING MATERIAL, INK, AND ADHESIVE 三菱ケミカル株式会社 2024-04-11 WO disclosed
EP-0439585-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. EPIPHARM ALLERGIE SERVICE (AT) 1991-08-07 EP disclosed
WO-1991002768-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1991-03-07 WO disclosed
EP-0199151-B1 LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1990-11-07 EP disclosed
US-4623661-A HYDROXAMIC ACID DERIVATIVES ABBOTT LABORATORIES (US) 1986-11-18 US disclosed
EP-0199151-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1986-10-29 EP disclosed
US-3903300-A Method for treating pain, fever and inflammation MERCK & CO INC 1975-09-02 US disclosed
US-3869506-A 1,2,10-Tricarboxy phenanthrene compounds MERCK & CO INC 1975-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064833-A1 COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS GRM2, GRIN2A, GRIN3A HPRT1 3384/4885ALDH1A1 4658/4885TDP1 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.